In Autumn 2020, DOAJ will be relaunching with a new website with updated functionality, improved search, and a simplified application form. More information is available on our blog. Our API is also changing.

Hide this message

Apatinib for molecular targeted therapy in tumor

Drug Design, Development and Therapy. 2015;2015(default):6075-6081


Journal Homepage

Journal Title: Drug Design, Development and Therapy

ISSN: 1177-8881 (Online)

Publisher: Dove Medical Press

LCC Subject Category: Medicine: Therapeutics. Pharmacology

Country of publisher: United Kingdom

Language of fulltext: English

Full-text formats available: PDF, HTML



Zhang H


Blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 16 weeks


Abstract | Full Text

Haijun Zhang Department of Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, People’s Republic of China Abstract: As tumor angiogenesis is one of the hallmarks of cancer, the inhibition of vascular endothelial growth factor signaling has become an attractive anticancer approach. Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor-2, has demonstrated encouraging anticancer activity across a broad range of malignancies, including gastric cancer, non-small-cell lung cancer, breast cancer, and hepatocellular carcinoma. In this up-to-date review, focus is not only on the structure, mechanisms, and pharmacokinetics of apatinib, but also on summarizing clinical trials and making recommendations of apatinib for patients with advanced solid tumors. Keywords: apatinib, angiogenesis, vascular endothelial growth factor receptor-2, molecular targeted therapy, tumor